BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 9988223)

  • 1. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease.
    Braun S; Hepp F; Sommer HL; Pantel K
    Int J Cancer; 1999 Feb; 84(1):1-5. PubMed ID: 9988223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.
    Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S
    Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plant Recycling for Molecular Biofarming to Produce Recombinant Anti-Cancer mAb.
    Kim DS; Song I; Kim J; Kim DS; Ko K
    Front Plant Sci; 2016; 7():1037. PubMed ID: 27486465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.
    Guo ZS; Lotze MT; Zhu Z; Storkus WJ; Song XT
    Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32664210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion.
    Wang H; Stoecklein NH; Lin PP; Gires O
    Oncotarget; 2017 Jan; 8(1):1884-1912. PubMed ID: 27683128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.
    Joshi P; Jacobs B; Derakhshan A; Moore LR; Elson P; Triozzi PL; Borden E; Zborowski M
    Oncotarget; 2014 May; 5(9):2450-61. PubMed ID: 24811334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role and clinical relevance of disseminated tumor cells in breast cancer.
    Banys M; Krawczyk N; Fehm T
    Cancers (Basel); 2014 Jan; 6(1):143-52. PubMed ID: 24434543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study.
    Luyckx V; Durant JF; Camboni A; Gilliaux S; Amorim CA; Van Langendonckt A; Irenge LM; Gala JL; Donnez J; Dolmans MM
    J Assist Reprod Genet; 2013 Oct; 30(10):1289-99. PubMed ID: 23989997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells.
    Jain J; Veggiani G; Howarth M
    Cancer Res; 2013 Apr; 73(7):2310-21. PubMed ID: 23378340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
    Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
    Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging technologies for CTC detection based on depletion of normal cells.
    Lustberg M; Jatana KR; Zborowski M; Chalmers JJ
    Recent Results Cancer Res; 2012; 195():97-110. PubMed ID: 22527498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interrelating dynamics of hypoxic tumor microenvironments and cancer cell phenotypes in cancer metastasis.
    Bartkowiak K; Riethdorf S; Pantel K
    Cancer Microenviron; 2012 Apr; 5(1):59-72. PubMed ID: 21626313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
    Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
    Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
    Boskovitz A; McLendon RE; Okamura T; Sampson JH; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):659-69. PubMed ID: 19647172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells.
    Balasubramanian P; Yang L; Lang JC; Jatana KR; Schuller D; Agrawal A; Zborowski M; Chalmers JJ
    Mol Pharm; 2009; 6(5):1402-8. PubMed ID: 19445481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer micrometastases.
    Pantel K; Alix-Panabières C; Riethdorf S
    Nat Rev Clin Oncol; 2009 Jun; 6(6):339-51. PubMed ID: 19399023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.
    Fehm T; Müller V; Alix-Panabières C; Pantel K
    Breast Cancer Res; 2008; 10 Suppl 1(Suppl 1):S1. PubMed ID: 19091005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A "class action" against the microenvironment: do cancer cells cooperate in metastasis?
    Bidard FC; Pierga JY; Vincent-Salomon A; Poupon MF
    Cancer Metastasis Rev; 2008 Mar; 27(1):5-10. PubMed ID: 18066649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients.
    Watson MA; Ylagan LR; Trinkaus KM; Gillanders WE; Naughton MJ; Weilbaecher KN; Fleming TP; Aft RL
    Clin Cancer Res; 2007 Sep; 13(17):5001-9. PubMed ID: 17785550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
    Cabioglu N; Sahin A; Doucet M; Yavuz E; Igci A; O Yildirim E; Aktas E; Bilgic S; Kiran B; Deniz G; Price JE
    Clin Exp Metastasis; 2005; 22(1):39-46. PubMed ID: 16132577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.